Thursday preview: AstraZeneca and Unilever report

AstraZeneca and Unilever will take centre stage Thursday when the FTSE 100 companies reveal their first quarter results.

AstraZeneca and Unilever will take centre stage Thursday when the FTSE 100 companies reveal their first quarter results.

Drug giant AstraZeneca is expected to report an earnings per share of $1.41, compared to the group's consensus of $1.37, according to Panmure Research.

"The stock has significantly outperformed the market this year and investors should look to taking profits as we do not expect these results to be catalysts to further outperformance," the broker said, reiterating a 'hold' recommendation.

Earlier this month, the biopharmaceutical business announced positive results from a study of fostamatinib, an oral drug being developed for the treatment of rheumatoid arthritis.

In the phase III study, designed to assess the efficacy and safety of fostamatinib, the drug achieved a "statistically significant improvement" in the ACR20 [American College of Rhematology] response rate in patients compared to a placebo.

Meanwhile, Panmure anticipates Unilever will deliver a healthy 6.0% like-for-like growth in the first quarter, slightly ahead the 5.6% consensus.

The consumer goods company last year reported its highest growth quarter with an 8.4% like-for-like growth.

Panmure said an unseasonably cold European March was likely to have affected ice-cream sales but an early Easter will provide some benefit.

"Unilever remains our favourite large cap stock given its ability to deliver superior growth from its attractive emerging market positions, although we would like to see it find more acquisitions given the successes of Alberto Culver and Kalina," the analyst said. It recommended a 'buy' rating.

Thursday April 25th

INTERNATIONAL ECONOMIC ANNOUNCEMENTS

Bloomberg Consumer Confidence (US) (14:45)

Continuing Claims (US) (13:30)

Initial Jobless Claims (US) (13:30)

Q3

AstraZeneca, Banco Santander SA, Polski Koncern Naftowy Orlen S.A. GDR(Reg S), Unilever

GMS

European Assets Trust NV (Regd)

IMSS

Admiral Group, Aer Lingus Group, AZ Electronic Materials SA (DI), British American Tobacco, Namakwa Diamonds Ltd. (DI), Playtech Ltd., Senior

AGMS

Acencia Debt Strategies Ltd., Admiral Group, Aggreko, ARC Capital Holdings Ltd, AstraZeneca, Barclays, Berendsen, Biome Technologies. BlackRock World Mining Trust, British American Tobacco, COLT Group SA, Croda International, Dialight, DP World Limited, Electric Word, EP Global Opportunities Trust, European Assets Trust NV (Regd), Filtrona PLC, Forbidden Technologies, Guaranty Trust Bank GDR (Reg S), International Personal Finance, JPMorgan Claverhouse Inv Trust, Kimberly Enterprises NV, Kolar Gold Ltd., Powerflute Oyj (DI), Premier Foods, SpaceandPeople, Synety Group, Taylor Wimpey, Tomco Energy, Volkswagen AG, Wolfson Microelectronics

UK ECONOMIC ANNOUNCEMENTS

GDP (Preliminary) (09:30)

Index of Services (09:30)

FINAL DIVIDEND PAYMENT DATE

Anglo American, Maintel Holdings, Shore Capital Group Ltd.

Q1

AstraZeneca, Banco Santander SA, Polski Koncern Naftowy Orlen S.A. GDR(Reg S), Unilever

RD

Recommended

Broker safety – your questions answered
Investment strategy

Broker safety – your questions answered

Cris Sholto Heaton answers more of your questions about the safety of stockbroker accounts
25 Mar 2020
How demographics affects stock valuations
Investment strategy

How demographics affects stock valuations

New research suggests that stock and bond valuations are driven by the age of the population – at least in the US.
24 Feb 2020
Do you own shares in Sirius Minerals? Here’s what you need to do now
Stocks and shares

Do you own shares in Sirius Minerals? Here’s what you need to do now

Mining giant Anglo American has proposed a cash takeover of Yorkshire-based minnow Sirius Minerals. Unhappy shareholders must decide whether to accept…
20 Feb 2020
Why investors should be “cautiously bullish” for 2020
Stockmarkets

Why investors should be “cautiously bullish” for 2020

Analysts have been out in force making rosy predictions for stockmarkets in 2020, but while there is certainly a case for optimism, investors should r…
17 Jan 2020

Most Popular

Here’s why you really should own at least some bitcoin
Bitcoin

Here’s why you really should own at least some bitcoin

While bitcoin is having a quiet year – at least in relative terms – its potential to become the default cash system for the internet is undiminished, …
16 Sep 2020
Will a second wave of Covid lead to another stockmarket crash?
Stockmarkets

Will a second wave of Covid lead to another stockmarket crash?

Can we expect to see another lockdown like in March, and what will that mean for your money? John Stepek explains.
18 Sep 2020
James Ferguson: How bad data is driving fear of a second wave of Covid-19
UK Economy

James Ferguson: How bad data is driving fear of a second wave of Covid-19

Merryn and John talk to MoneyWeek regular James Ferguson about the rise in infections in coronavirus and what the data is really telling us.
17 Sep 2020